Overview
Cardiogen is sold as a cardiac peptide bioregulator in the Khavinson family. It is catalogued here for completeness, with a clear warning: of all the compounds in this family, Cardiogen has the weakest documentary basis.
A PubMed search for Cardiogen as a peptide returned no results at all. Unlike Vilon, Livagen, Cortagen, Testagen, Bronchogen, Chonluten and Crystagen — each of which appears in at least one indexed study — no indexed biomedical literature for Cardiogen as a cardiac peptide was located.
The sequence situation is worse. Vendor listings commonly give Cardiogen as Ala-Glu-Asp-Pro (AEDP), but AEDP is firmly established as Cortagen, confirmed by both PubChem (CID 18439621, CAS 335591-03-2) and the published chromatin literature. Other listings give Ala-Glu-Asp-Arg (AEDR). A PubChem search for the name Cardiogen returns L-carnitine — an entirely different molecule that is not a peptide at all — which indicates the name is not a registered chemical identity. Searching PubChem for Ala-Glu-Asp-Gly returns Epithalon, not Cardiogen.
In short: the marketed sequence contradicts an established assignment, no chemical registry entry corresponds to the name, and no biomedical literature exists. Anyone sourcing this compound cannot verify what they are receiving against any public reference.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- None located.
- AnimalRodent and other animal models
- None located.
- In vitroCell and tissue studies
- None located.
Key studies & findings
2 studies- 1
A PubMed search for Cardiogen as a cardiac peptide returned no indexed results. No study of this compound was located.
- 2
The commonly marketed Ala-Glu-Asp-Pro sequence is established as Cortagen (PubChem CID 18439621, CAS 335591-03-2), not Cardiogen, and a PubChem name search for Cardiogen returns L-carnitine — a non-peptide — indicating no registered chemical identity under this name.
Benefits & effects
No benefit data has been compiled for this entry yet.
Side effects & safety
1 reportedSafety noteResearch compound for laboratory use only. No regulatory safety review, no established human safety database, and no controlled toxicology data in the public literature.
Recorded in the cited literature No controlled human safety data exist for this compound · No confirmed chemical identity — material cannot be verified against any public reference.
Marketed sequence conflicts with an established assignment for a different peptide
Limitations & open questions
This compound has no indexed biomedical literature, no confirmed amino acid sequence, and no chemical registry entry matching its trade name. The sequence most commonly advertised for it (Ala-Glu-Asp-Pro) belongs to a different peptide, Cortagen. Every claim made for Cardiogen in the marketplace is therefore unsupported by any source that can be checked. It is listed here so that this can be stated plainly, not because there is anything to report.
Pharmacology
No chemical identity could be confirmed for this compound. No molecular formula, molecular weight, CAS number, PubChem CID or pharmacokinetic data are available under this name.
Frequently asked questions
Is Cardiogen AEDP?
No. AEDP is Cortagen, confirmed by PubChem CID 18439621 (C17H26N4O9, CAS 335591-03-2) and by the published chromatin literature, which names Ala-Glu-Asp-Pro as Cortagen directly. Vendor listings assigning AEDP to Cardiogen are in conflict with both sources.
Is there any research on Cardiogen?
None was located. A PubMed search for Cardiogen as a cardiac peptide returned zero results, in contrast to other members of this family which each have at least one indexed study.
Why is it listed at all if there is no evidence?
Because it is sold, and the absence of evidence is itself the useful information. A catalogue that silently omits it leaves buyers to assume the research exists somewhere.
Citations
1 sources- 1